Exposure-Guided and Individualized Dalbavancin Therapy beneficial in Staphylococcus aureus Bacteremia: JAMA

This research was carried out as an exploratory analysis of DOTS, the “Dalbavancin as an Option for Treatment of S. aureus Bacteremia” clinical trial. This is a multicenter, randomized, open-label, and assessor-blind study. It was conducted from April 2021 through December 2023. Data analysis lasted from January 2024 through December 2025. A total of 97 adults were recruited in the study. They were the ones who had undergone bloodstream clearance of complicated S. aureus bacteremia.

The subjects in the study had a mean age of 54.5 years (15.8 SD) and were mostly male, at 71.1%. They supplied 640 PK samples. The drug administration involved an administration of 1500 mg of dalbavancin intravenously on days 1 and 8 with the dose being reduced to 1125 mg for participants with severe renal impairment who were not undergoing dialysis.

Key findings:

• Individual exposure measures were obtained using nonlinear mixed-effects population pharmacokinetic (PK) analysis.
• The drug clearance was found to be 0.066 L/h (95% CI, 0.062 to 0.069 L/h), and the central volume of distribution to be 5.67 L (95% CI, 5.37 to 5.99 L).
• Drug clearance depended on creatinine clearance through a power function (power of 0.21).
• Distribution volumes depended on the body weight, with a central volume of 0.57 and a third peripheral volume of 0.56.
• In addition, albumin levels were negatively correlated with the second peripheral volume (power of -0.81) and the unbound fraction scaling factor (power of -0.78), while age was positively correlated with the third peripheral volume (power of 0.63).
• Out of the 93 evaluable subjects, 72 (77.4%) were classified as successful by day 70.
• The success rate, however, differed significantly between patients who had day 22 levels of > 32 μg/mL and those whose day 22 levels were 32 μg/mL or less.
• In patients with high drug exposure (n = 30), the success rate was an impressive 96.7% (n = 29), while in those with low exposure (n = 63), it was 68.3% (n = 43).
• This corresponds to an increased difference in success of 25.3 percentage points (95% confidence interval, 3.5 to 47.0).
• Notably, no greater complications arose from the use of the higher dosage; serious adverse events occurred in 26.7% of patients with high exposure versus 42.9% of those with low exposure.

The results of this study have shown that the pharmacokinetics of dalbavancin were predictable based on renal function, body mass, albumin concentrations, and age, with elevated concentrations on day 22 being indicative of success without more serious side effects. In contrast to the trend toward shorter antibiotic courses, Staphylococcus aureus bloodstream infections require a tailored and possibly extended treatment approach. Maintaining adequate therapeutic levels beyond bacteremia clearance and source control is essential for optimal outcomes.However Future research should focus on identifying patients who may benefit from additional dalbavancin doses, determining optimal dosing schedules, and validating intensified or therapeutic drug monitoring–guided strategies.

Reference:

Lodise TP, Turner NA, Hamasaki T, et al. Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial. JAMA Netw Open. 2026;9(4):e2611652. doi:10.1001/jamanetworkopen.2026.11652